Bente Steffansen

Bente Steffansen

Auto-generated profile, based on publicly available information

Bente Steffansen

Department of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230 Odense M, Denmark

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
BBBirger Brodin
Birger Brodin
Carsten Uhd NielsenCarsten Uhd Nielsen
Carsten Uhd Nielsen
BSBente Steffansen
Bente Steffansen
SFSven Frøkjær
Sven Frøkjær

1 November 1997 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
MCM. Chen
M. Chen
SCSøren Brøgger Christensen
Søren Brøgger Christensen
LZL. Zhai
L. Zhai
MRM. H. Rasmussen
M. H. Rasmussen
TTT. G. Theander
T. G. Theander
AKA. Kharazmi
A. Kharazmi
Previous studies have shown that licochalcone A, an oxygenated chalcone, exhibits antileishmanial and antimalarial activities. The present study was

1 January 2004 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
BSBente Steffansen
Bente Steffansen
Carsten Uhd NielsenCarsten Uhd Nielsen
Carsten Uhd Nielsen
BBBirger Brodin
Birger Brodin
AEAndré Huss Eriksson
André Huss Eriksson
RARikke Andersen
Rikke Andersen
SFSven Frokjaer
Sven Frokjaer

1 July 2001 in American Journal of Physiology-Gastrointestinal and Liver Physiology
Verified
Journal Article
Closed access
PDF file
Carsten Uhd NielsenCarsten Uhd Nielsen
Carsten Uhd Nielsen
JAJan Amstrup
Jan Amstrup
BSBente Steffansen
Bente Steffansen
SFSven Frokjaer
Sven Frokjaer
BBBirger Brodin
Birger Brodin
The human intestinal cell line Caco-2 was used as a model system to study the effects of epidermal growth factor (EGF) on peptide transport. EGF decreased apical-to-basolateral fluxes of [14C]glycylsarcosine ([14C]Gly-Sar) up to 50.2 ± 3.6% ( n = 6) of control values. Kinetic analysis of the fluxes showed that maximal flux ( Vmax) of transepithelial transport decreased from 3.00 ± 0.17 nmol · cm−2· min−1in control cells to 0.50 ± 0.07 nmol · cm−2· min−1in cells treated with 5 ng/ml EGF ( n = 6, P < 0.01). The apparent Michaelis-Menten constant ( Km) was 2.71 ± 0.31 mM ( n= 6) in control cells and 1.89 ± 0.28 mM ( n = 6, not significantly different from control) in EGF-treated cells. Similarly, apical uptake of [14C]Gly-Sar decreased in cells treated with EGF, with an ED50value of 0.36 ± 0.06 ng/ml ( n = 6) EGF and a maximal inhibition of 80 ± 0.02% ( n = 6). Vmaxdecreased from 2.61 ± 0.4 to 1.06 ± 0.1 nmol · cm−2· min−1( n = 3, P < 0.05), whereas Kmremained constant. Basolateral Gly-Sar uptake showed no changes in Vmaxor Kmafter EGF treatment ( n = 3). RT-PCR showed a decrease in hPepT1 mRNA (using glucose-6-phosphate dehydrogenase mRNA as control) in cells treated with EGF. Western blotting indicated a decrease in hPepT1 protein in cell lysates. We conclude that EGF treatment decreases Gly-Sar transport in Caco-2 cells by decreasing the number of peptide transporter molecules in the apical membrane.

27 August 2001 in Journal of Controlled Release
Verified
Journal Article
Closed access
Carsten Uhd NielsenCarsten Uhd Nielsen
Carsten Uhd Nielsen
RARikke Andersen
Rikke Andersen
BBBirger Brodin
Birger Brodin
SFSven Frokjaer
Sven Frokjaer
MTMitchell E Taub
Mitchell E Taub
BSBente Steffansen
Bente Steffansen

1 July 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
AAAhmed A. Abdulhussein Al-Ali
Ahmed A. Abdulhussein Al-Ali
RNRasmus Blaaholm Nielsen
Rasmus Blaaholm Nielsen
BSBente Steffansen
Bente Steffansen
RHRené Holm
René Holm
Carsten Uhd NielsenCarsten Uhd Nielsen
Carsten Uhd Nielsen